Last update 01 Jun 2025

Camptothecin(Calando Pharmaceuticals, Inc.)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CRLX-101, IT-101, NLG207
Action
inhibitors
Mechanism
HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Active Indication
Originator Organization
Active Organization
License Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic castration-resistant prostate cancerPhase 2
United States
26 Mar 2019
Recurrent ovarian cancerPhase 2
United States
01 Jul 2015
Recurrent Primary Peritoneal CarcinomaPhase 2
United States
01 Jul 2015
Metastatic Renal Cell CarcinomaPhase 2
United States
01 Jul 2014
Extensive stage Small Cell Lung CancerPhase 2
United States
16 Jan 2013
Recurrent Lung Small Cell CarcinomaPhase 2
United States
16 Jan 2013
Adenocarcinoma of EsophagusPhase 2
United States
01 Nov 2012
Advanced Gastric AdenocarcinomaPhase 2
United States
01 Nov 2012
Advanced Gastroesophageal Junction AdenocarcinomaPhase 2
United States
01 Nov 2012
Esophageal Squamous Cell CarcinomaPhase 2
United States
01 Nov 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
4
podedzucvx = edaeyfnann ylwgvsruoc (gbfvhnbfil, nvdaibayhp - swpouzcure)
-
12 Jul 2022
Phase 2
63
dqbsmzqvqr(umrbppnjfc) = nwdzbojicn ksxpnptqvi (wuhybvdwps )
Positive
01 Sep 2021
bevacizumab+CRLX101
dqbsmzqvqr(umrbppnjfc) = wctnmfktsr ksxpnptqvi (wuhybvdwps )
Phase 1/2
32
dhcnyhbfff(tnqlxmgtgd) = iyghvxrhuf iksrnjurbu (wucgwyeypm )
-
01 Jun 2019
Phase 2
10
ulsadvzsne = ibpthndhur wpcrwjbvay (kduakcnkbz, bpzvgxwbqh - ejaxdlksjo)
-
27 Dec 2017
Phase 1/2
32
(Dose Escalation Phase Ib)
xuwwynlsyv = nughtdhqdk wsxtnkdstb (kdxckjovcl, ygodptehuj - txwmrofmnk)
-
14 Nov 2017
(All Participants)
cibzdzavmy = ggplyrimpd xyjvzxiitr (zlrdqcuhul, lkltwokssb - btncjzuwxl)
Phase 2
Advanced Renal Cell Carcinoma
Third line | Second line
111
zzjnsabmoa(nsmyhaxpgc) = jwijjklffa uhfoovoeoi (erntuymtrk, 2.0 - 4.3)
Negative
01 Nov 2017
standard of care
zzjnsabmoa(nsmyhaxpgc) = dogcazeoxi uhfoovoeoi (erntuymtrk, 2.2 - 5.4)
Phase 1/2
32
CRLX101 12 mg/m^2 QOW
iopstdpatx(eeeelzgnjy) = Mean neoadjuvant rectal (NAR) score was 19 with standard deviation of 15. At the weekly MTD, 3/6 patients had pCR. xeoufpiltm (fbawummkwt )
Positive
01 Oct 2017
CRLX101 15 mg/m^2 QOW
Phase 2
157
(CRLX101)
lvlvkkaufv(ukzvehyrpb) = kuijivzlhf aayslcfjdd (joykirxcqu, ustrrnssol - emqjvcleex)
-
24 May 2017
Best Supportive Care
(Best Supportive Care)
lvlvkkaufv(ukzvehyrpb) = dkmbjzbpqq aayslcfjdd (joykirxcqu, bhonxrshcg - pjvgmqjzih)
Phase 1/2
22
fmypdaylvi(ckbuvyklog) = Grade ≥3 AEs related to CRLX101 included non-infectious cystitis (5 events), fatigue (3 events), anemia (2 events), diarrhea (2 events), dizziness (2 events), and 7 other individual events avvvzoerth (hzgiavmdiq )
Positive
01 Aug 2016
Phase 2
18
CRLX101 + Avastin
qolpxewgrz(dvjhupobje) = utdwpfsuky dwlutmrafi (nnmmqoaitw )
Positive
15 Jul 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free